Patents Assigned to IMBA-INSTITUT FUR MOLEKULARE BIOTECHNOLOGIE GmbH
  • Three dimensional heterogeneously differentiated tissue culture
    Patent number: 11345889
    Abstract: The present invention provides an artificial tissue culture comprising a heterogeneous population of cells of at least two different tissue sections, wherein said tissue sections are in a three dimensional structure, method of generating such a tissue and kits suitable for said method or maintain a three dimensional tissue culture.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: May 31, 2022
    Assignee: IMBA-Institut fur Molekulare Biotechnologie GMBH
    Inventors: Juergen Knoblich, Madeline A. Lancaster
  • BREAST CANCER THERAPEUTICS
    Publication number: 20190030161
    Abstract: The present invention relates to a method of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of a RANKL inhibitor to said patient.
    Type: Application
    Filed: October 12, 2018
    Publication date: January 31, 2019
    Applicant: IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Josef PENNINGER, Daniel SCHRAMEK
  • BREAST CANCER DIAGNOSTICS USING RANKL AND OPG
    Publication number: 20170102388
    Abstract: The present invention relates to methods and means for detecting cancer or of predicting a patient developing cancer or of determining the rate of progression of cancer in a patient suffering from cancer, comprising determining RANKL activity and/or the amount of OPG in a sample of said patient.
    Type: Application
    Filed: December 27, 2016
    Publication date: April 13, 2017
    Applicant: IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Josef PENNINGER, Daniel SCHRAMEK, Georg SCHETT, Martin WIDSCHWENDTER, Ian J. JACOBS, Usha MENON
  • Archease as RNA ligaes complex member
    Patent number: 9296994
    Abstract: The present invention relates to the use of Archease proteins as RNA ligase enhancer, methods of ligating RNA molecules, kits for these methods and uses and transgenic cells.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: March 29, 2016
    Assignee: IMBA-INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Johannes Popow, Javier Martinez, Anne Nielsen, Alexander Schleiffer, Theresa Henkel
  • THREE DIMENSIONAL HETEROGENEOUSLY DIFFERENTIATED TISSUE CULTURE
    Publication number: 20150330970
    Abstract: The present invention provides an artificial tissue culture comprising a heterogeneous population of cells of at least two different tissue sections, wherein said tissue sections are in a three dimensional structure, method of generating such a tissue and kits suitable for said method or maintain a three dimensional tissue culture.
    Type: Application
    Filed: December 13, 2013
    Publication date: November 19, 2015
    Applicant: IMBA - Institut Fur Molekulare Biotechnologie GMBH
    Inventors: Jurgen Knoblich, Madeline A. Lancester
  • HAPLOID CELLS
    Publication number: 20140342369
    Abstract: The present invention relates to the generation of stable haploid cell cultures, uses of said cells in forward and reverse genetics, especially the identification of target genes associated with a modified phenotype and in particular identifying genetic targets associated with toxin resistance, especially ricin toxicity resistance, and therapeutic uses of target compounds.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 20, 2014
    Applicant: IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Ulrich Elling, Josef Penninger, Jasmin Taubenschmid
  • BREAST CANCER DIAGNOSTICS
    Publication number: 20130316374
    Abstract: The present invention relates to methods and means for detecting cancer or of predicting a patient developing cancer or of determining the rate of progression of cancer in a patient suffering from cancer, comprising determining RANKL activity and/or the amount of OPG in a sample of said patient.
    Type: Application
    Filed: September 22, 2011
    Publication date: November 28, 2013
    Applicant: IMBA - INSTITUT FUR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Josef Penninger, Daniel Schramek, Georg Schett, Martin Widschwendter, Ian J. Jacobs, Usha Menon
  • ARCHEASE AS RNA LIGASE COMPLEX MEMBER
    Publication number: 20130280763
    Abstract: The present invention relates to the use of Archease proteins as RNA ligase enhancer, methods of ligating RNA molecules, kits for these methods and uses and transgenic cells.
    Type: Application
    Filed: April 23, 2013
    Publication date: October 24, 2013
    Applicant: IMBA - INSTITUT FUR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Johannes POPOW, Javier MARTINEZ, Anne NIELSEN, Alexander SCHLEIFFER
  • BREAST CANCER THERAPEUTICS
    Publication number: 20130216550
    Abstract: The present invention relates to a method of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of a RANKL inhibitor to said patient.
    Type: Application
    Filed: September 22, 2011
    Publication date: August 22, 2013
    Applicant: IMBA-INSTITUT FUR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Josef Penninger, Daniel Schramek
  • USE OF A HSPC117 MOLECULE AS RNA LIGASE
    Publication number: 20130156748
    Abstract: The present invention relates to the use of HSPC117 molecules as RNA ligase, methods of ligating RNA molecules, kits for these methods and uses and transgenic cells.
    Type: Application
    Filed: August 30, 2011
    Publication date: June 20, 2013
    Applicant: IMBA-Institut fur Molekulare Biotechnologie GmbH
    Inventors: Johannes Popow, Stefan Weitzer, Javier Martinez, Karl Mechtler, Alexander Schleiffer
  • Methods for Identifying Inhibitors of the Type III Secretion System
    Publication number: 20130130283
    Abstract: A method for determining whether a test compound has the ability to inhibit the function of the type 3 secretion system. In a first step, the compound is tested for its ability to inhibit secretion of an effector and/or a translocator protein, in a second step, it is further tested for its ability to inhibit the assembly of the structural components to form the needle complex. By this method, drug candidates can be identified that are highly specific anti-bacterial agents for treating diseases caused by Gram-negative bacteria with a T3SS.
    Type: Application
    Filed: March 22, 2011
    Publication date: May 23, 2013
    Applicant: IMBA - Institut fur Molekulare Biotechnologie GMBH
    Inventors: Thomas C. Marlovits, Julia Radics, Wolfgang Schmied
  • Methods for modulating the proliferation and differentiation potential of stem cells and progenitor cells
    Patent number: 8431398
    Abstract: Modulators of TRIM-NHL proteins and their use for modulating the proliferation and differentiation potential of stem cells and progenitor cells. Inhibitors of TRIM-NHL proteins, e.g. TRIM32, are useful for stem cell maintenance in vitro and in vivo. Assay methods for identifying TRIM-NHL protein modulators make use of the E3 ligase activity of TRIM32 or its interaction with Argonaute-1.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: April 30, 2013
    Assignee: IMBA-Institut fur Molekulare Biotechnologie GmbH
    Inventors: Juergen Knoblich, Jens Schwamborn
  • METHODS FOR MODULATING THE PROLIFERATION AND DIFFERENTIATION POTENTIAL OF STEM CELLS AND PROGENITOR CELLS
    Publication number: 20100317563
    Abstract: Modulators of TRIM-NHL proteins and their use for modulating the proliferation and differentiation potential of stem cells and progenitor cells. Inhibitors of TRIM-NHL proteins, e.g. TRIM32, are useful for stem cell maintenance in vitro and in vivo. Assay methods for identifying TRIM-NHL protein modulators make use of the E3 ligase activity of TRIM32 or its interaction with Argonaute-1.
    Type: Application
    Filed: September 19, 2008
    Publication date: December 16, 2010
    Applicant: IMBA-INSTITUT FUR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Juergen Knoblich, Jens Schwamborn
  • Use of a Compound with RANKL Activity
    Publication number: 20090162426
    Abstract: The present invention relates to the use of a compound with receptor activator of nuclear factor-kB ligand (RANKL) activity for the manufacture of a topical pharmaceutical formulation for the modulation of local or systemic Treg numbers and the treatment or the prevention of skin-associated or systemic diseases.
    Type: Application
    Filed: May 8, 2007
    Publication date: June 25, 2009
    Applicant: IMBA-INSTITUT FUR MOLEKULARE BIOTECHNOLOGIE GmbH
    Inventors: Josef Penninger, Karin Loser, Stefan Beissert